Influence of Herbesser Capsules on no-reflow, heart function and inflammatory factors in patients with acute coronary syndrome during percutaneous coronary intervention
SONG Xian-xian
ZHANG Xu-tao
YAN Chang-hao
LIU Ai-ming
Abstract：Objective To investigate the influence of Herbesser Capsules on heart function, no-reflow phenomenon and serum cytokine level in in patients with acute coronary syndrome (ACS) during percutaneous coronary intervention (PCI).Methods ACS patients (n=150) with no-reflow phenomenon after PCI were chosen from the Department of Cardiology of Chinese Medicine Hospital in Jianshi County from Jan. 2012 to Feb. 2015, and randomly divided into Herbesser Capsules group treated with Herbesser Capsules and routine group treated with nitroglycerin (eachn=75). The changes of no-reflow phenomenon, heart function and serum cytokines level were observed in 2 groups at different time points before and after treatment.Results The differences in of thrombolysis in myocardial infarction (TIMI) grade and corrected TIMI frame count (CTFC) had no statistical significance between 2 groups before treatment (P>0.05). After treatment for 10 min and 20 min, TIMI grade were significantly higher (P<0.05) and CTFC was significantly lower in Herbesser Capsules group than those in routine group (P<0.05). After treatment for 1 w, left ventricular ejection fraction (LVEF) was significantly higher, and left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI) were significantly lower in Herbesser Capsules group than those in routine group (P<0.05). The levels of C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and P-selectin were significantly lower in Herbesser Capsules group than those in routine group after PCI for 1 w (P<0.05). The differences in prognosis and complication incidence had no statistical significance between 2 groups (P>0.05) during 12-month follow-up period after PCI.Conclusion The administration of Herbesser Capsules can improve heart function, relieve inflammatory reactions and reduce no-reflow phenomenon in ACS patients during PCI.
Keywords：Acute coronary syndromePercutaneous coronary interventionHerbesser CapsulesHeart functionNo-reflow phenomenonCytokines
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 979-982 )